C086, a novel analog of curcumin, induces growth inhibition and downregulation of NFκB in colon cancer cells and xenograft tumors

Cancer Biology and Therapy

Volumn 12, Issue 9, 2011, Pages 797-807

  Chen, Chun ^a   Liu, Yang ^a   Chen, Yuanzhong ^b   Xu, Jianhua ^a  

^a School of Pharmacy   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Analog; Angiogenesis; Cancer; Curcumin; I B; NF B; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; C 086; CD31 ANTIGEN; CURCUMIN; CYCLIN D1; CYCLINE; FLUOROURACIL; GELATINASE B; GENE PRODUCT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMIN B; MATRIGEL; MYC PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; GEL BLOT ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUDE MOUSE; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; I-KAPPA B PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80655130239     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.9.17671     Document Type: Article

References (44)

1. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3:768-80; PMID:14570043; DOI:10.1038/nrc1189.
2. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor- 2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000; 275:10405-12; PMID:10744729; DOI:10.1074/jbc.275.14.10405.
3. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999; 59:597-601. (Pubitemid 29076056)
4. Chen H, Zhang ZS, Zhang YL, Zhou DY. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 1999; 19:3675-80; PMID:10625938.
5. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14:4491-9; PMID:18628464; DOI:10.1158/1078-0432. CCR-08-0024.
6. Mosley CA, Liotta DC, Snyder JP. Highly active anticancer curcumin analogues. Adv Exp Med Biol 2007; 595:77-103; PMID:17569206; DOI:10.1007/978-0-387-46401-5-2.
7. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269:199-225; PMID:18479807; DOI:10.1016/j.canlet.2008.03.009.
8. Arbiser JL, Klauber N, Rohan R, van Leeuwen R, Huang MT, Fisher C, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998; 4:376-83; PMID:10780880.
9. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007; 13:3423-30; PMID:17545551; DOI:10.1158/1078-0432.CCR-06-3072.
10. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65:1631-52; PMID:18324353; DOI:10.1007/s00018-008-7452-4.
11. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their downregulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101:2351-62; PMID:15476283; DOI:10.1002/cncr.20605.
12. Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16:475-83; PMID:16788380; DOI:10.1097/01.fpc.0000220562.67595.a5.
13. Cho YB, Lee WY, Song SY, Shin HJ, Yun SH, Chun HK. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol 2007; 38:1603-10; PMID:17669467; DOI:10.1016/j.humpath.2007.03.018.
14. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1:11-21; PMID:11900248; DOI:10.1038/35094017.
15. Singh S, Aggarwal BB. Activation of transcription factor NFkappaB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270:24995-5000; PMID:7559628; DOI:10.1074/jbc.270.42.24995.
16. Sandur SK, Deorukhkar A, Pandey MK, Pabon AM, Shentu S, Guha S, et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NFkappaB activity. Int J Radiat Oncol Biol Phys 2009; 75:534-42; PMID:19735878; DOI:10.1016/j.ijrobp.2009.06.034.
17. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. Curcumin-induced suppression of cell proliferation correlates with downregulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002; 21:8852-61; PMID:12483537; DOI:10.1038/sj.onc. 1206048.
18. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 2002; 23:143-50; PMID:11756235; DOI:10.1093/carcin/23.1.143.
19. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 1998; 55:775-83; PMID:9586949; DOI:10.1016/S0006-2952(97)00557-1.
20. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) downregulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006; 69:195-206; PMID:16219905.
21. Garg A, Aggarwal BB. Nuclear transcription factorkappaB as a target for cancer drug development. Leukemia 2002; 16:1053-68; PMID:12040437; DOI:10.1038/sj.leu.2402482.
22. Karin M. NFkappaB and cancer: mechanisms and targets. Mol Carcinog 2006; 45:355-61; PMID:16673382; DOI:10.1002/mc.20217.
23. Takayama T, Goji T, Taniguchi T, Inoue A. Chemoprevention of colorectal cancer-experimental and clinical aspects. J Med Invest 2009; 56:1-5; PMID:19262006; DOI:10.2152/jmi.56.1.
24. Horst D, Budczies J, Brabletz T, Kirchner T, Hlubek F. Invasion associated upregulation of nuclear factor kappaB target genes in colorectal cancer. Cancer 2009; 115:4946-58; PMID:19658179; DOI:10.1002/cncr.24564.
25. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002; 11:535-40; PMID:12050094.
26. Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, et al. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 2000; 21:921-7; PMID:10783313; DOI:10.1093/carcin/21.5.921.
27. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 2002; 8:1695-706; PMID:12171541; DOI:10.2174/1381612023394016.
28. Cen L, Hutzen B, Ball S, DeAngelis S, Chen CL, Fuchs JR, et al. New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells. BMC Cancer 2009; 9:99; PMID:19331692; DOI:10.1186/1471-2407-9-99.
29. Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006; 5:2563-71; PMID:17041101; DOI:10.1158/1535-7163.MCT-06-0174.
30. Shibata H, Yamakoshi H, Sato A, Ohori H, Kakudo Y, Kudo C, et al. Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci 2009; 100:956-60; PMID:19445025; DOI:10.1111/j.1349-7006.2009.01127.x.
31. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009; 125:2187-97; PMID:19623659; DOI:10.1002/ijc.24593.
32. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis and angiogenesis in colorectal cancer. Mol Cancer Ther 2007; 6:1276-82; PMID:17431105; DOI:10.1158/1535-7163. MCT-06-0556.
33. Shpitz B, Giladi N, Sagiv E, Lev-Ari S, Liberman E, Kazanov D, et al. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006; 74:140-4; PMID:17228149; DOI:10.1159/000098655.
34. Giménez-Bonafé P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009; 9:320-40; PMID:19442052; DOI:10.2174/156800909788166600.
35. Wu K, Bonavida B. The activated NFkappaB-Snail- RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 2009; 29:241-54; PMID:19538137.
36. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005; 12:37-46; PMID:16113098; DOI:10.1677/erc.1.00977.
37. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18:6938-47; PMID:10602468; DOI:10.1038/sj.onc.1203221.
38. Richmond A. NfkappaB, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002; 2:664-74; PMID:12209135; DOI:10.1038/nri887.
39. Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, et al. Inhibition of IkappaB kinase-nuclear factorkappaB signaling pathway by 3,5-bis(2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 2008; 74:654-61; PMID:18577686; DOI:10.1124/mol.108. 046201.
40. Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, et al. Curcumin analog GO-Y030 is a novel inhibitor of IKKbeta that suppresses NFkappaB signaling and induces apoptosis. Cancer Sci 2011; 102:1045-51; PMID:21272158; DOI:10.1111/j.1349-7006.2011.01886.x.
41. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-8; PMID:7926468.
42. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23:2840-55; PMID:15837998; DOI:10.1200/JCO.2005. 09.051.
43. Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N. Downregulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol 2006; 4:21-6; PMID:16737669.
44. Bhattacharya N, Sarno A, Idler IS, Fuhrer M, Zenz T, Dohner H, et al. High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay. Int J Cancer 2010; 127:404-11; PMID:19924814.